Deutsche Bank AG restated their buy rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Wednesday. The firm currently has a GBX 5,800 ($75.71) price target on the biopharmaceutical company’s stock.
AZN has been the subject of several other research reports. Jefferies Group reiterated a hold rating on shares of AstraZeneca plc in a research report on Monday, June 6th. Berenberg Bank set a GBX 5,550 ($72.44) price target on shares of AstraZeneca plc and gave the stock a buy rating in a research report on Thursday, August 25th. HSBC reiterated a hold rating and set a GBX 4,240 ($55.35) price target on shares of AstraZeneca plc in a research report on Friday, June 17th. Citigroup Inc. restated a buy rating on shares of AstraZeneca plc in a report on Wednesday, July 27th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price objective on shares of AstraZeneca plc and gave the company a sell rating in a report on Wednesday, August 10th. Five equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. AstraZeneca plc currently has an average rating of Hold and an average target price of GBX 4,926.80 ($64.31).
AstraZeneca plc (LON:AZN) opened at 5026.00 on Wednesday. The firm’s market cap is GBX 63.58 billion. The stock’s 50 day moving average is GBX 5,007.50 and its 200 day moving average is GBX 4,415.10. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00.
The company also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were given a dividend of GBX 68.70 ($0.90) per share. This represents a yield of 1.37%. The ex-dividend date was Thursday, August 11th.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.